ERT announced the integration of a wearable biosensor which captures and wirelessly transmits real-time, continuous, clinical-grade biometric measurements into the ERT electronic Clinical Outcome Assessment (eCOA) system. ERT showcased a proof-of-concept demonstration of the integration at its Innovation Lab at the Drug Information Association (DIA) Annual Meeting, June 14-17, in Washington, D.C.

Atrial fibrillation patients on the anticoagulant dabigatran were more likely to adhere to the medication with appropriate patient selection and pharmacist-led monitoring, according to a study in the April 14 issue of JAMA. The study looked at patients who filled dabigatran prescriptions at Veterans Health Administration (VHA) sites, and found variability in patient medication adherence across sites.

IMRIS Inc. received a letter May 26 from the NASDAQ Stock Market stating that it would be delisted and trading suspended on June 4. IMRIS said this was in accordance with Listing Rules 5101, 5110(b), and IM-5101-1. A Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC), which will remove the company's securities from listing and registration on The Nasdaq Stock Market.